本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kiniksa Pharmaceuticals Ltd.

80.20
+0.82001.03%
盤後80.200.00000.00%19:30 EDT
成交量:40.21萬
成交額:3,214.76萬
市值:62.58億
市盈率:81.01
高:80.86
開:79.36
低:79.13
收:79.38
52周最高:82.94
52周最低:32.89
股本:7,802.40萬
流通股本:4,019.47萬
量比:0.81
換手率:1.00%
股息:- -
股息率:- -
每股收益(TTM):0.9900
每股收益(LYR):0.7500
淨資產收益率:14.04%
總資產收益率:8.05%
市淨率:9.57
市盈率(LYR):106.93

資料載入中...

2024/11/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/10/29

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/29

重要事件披露

Form 8-K - Current report
2024/10/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/10/08

超過5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/10/08

重要事件披露

Form 8-K - Current report
2024/09/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/27

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/25

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/23

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/23

摘牌通告

Form 15-15D/A - Suspension of duty to report [Section 13 and 15(d)]: [Amend]
2024/07/23

重要事件披露

Form 8-K - Current report
2024/07/02

SEC問詢函

Form CORRESP - Correspondence
2024/06/28

摘牌通告

Form 15-15D - Suspension of duty to report [Section 13 and 15(d)]
2024/06/28

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/06/28

員工持股計劃

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments